FIELD: medicine.
SUBSTANCE: invention refers to chemical-pharmaceutical industry and medicine, namely to pharmaceutical compositions for the oral medical products applied in the integrated treatment of menopause osteoporosis in women. There is offered pharmaceutical composition which contains one or more active substances mainly with different therapeutic modalities providing intensified osteogenesis or decreased bone resorption, an element-vitamin complex containing elements in the form of physiologically acceptable compounds, providing intensified bone formations and decreased bone resorption, and the vitamins intensifying therapeutic action of the active substances and ensuring intensified bone formation and decreased resorption, and an excipient in the form of one substance or mixed substances which is monoexcipient or one component of the excipient.
EFFECT: higher effectiveness of the composition.
6 cl, 13 tbl, 8 ex
| Title | Year | Author | Number |
|---|---|---|---|
| SYGETHIN-BASED PHARMACEUTICAL STRUCTURE FOR OSTEOPOROSIS PREVENTION AND TREATMENT (VERSIONS) | 2007 |
|
RU2356546C1 |
| PHARMACEUTICAL COPMOSITIONS DISSOLVING IN ORAL CAVITY | 2005 |
|
RU2405541C2 |
| PHARMACEUTICAL COMPOSITIONS CONTAINING BISPHOSPHONATE DERIVATIVES AND HIGH DOSES OF CHOLECALCIFEROL | 2010 |
|
RU2533230C2 |
| PHARMACEUTICAL COMPOSITION FOR TREATING JOINT AND BONE TISSUE DISEASES | 2013 |
|
RU2547572C2 |
| LOCAL AND EXTERNAL SYGETHIN-BASED PHARMACEUTICAL COMPOSITION FOR MENOPAUSAL DISORDERS PREVENTION AND TREATMENT | 2007 |
|
RU2356548C1 |
| PHARMACEUTICAL PREPARATION FOR EXTERNAL AND LOCAL APPLICATION, BASED ON SYGETHIN | 2007 |
|
RU2363461C2 |
| ANTI-OSTEOPOROSIS AGENT | 2015 |
|
RU2582973C1 |
| COMPOSITION FOR PROVIDING PREVENTIVE MEASURES AGAINST CALCIC DEFICIENCY AND NORMALISATION OF CALCIUM METABOLISM (VERSIONS) | 2008 |
|
RU2376890C1 |
| TREATMENT OF OSTEOPOROSIS | 2010 |
|
RU2562976C2 |
| BIOLOGICALLY ACTIVE FOOD SUPPLEMENT FOR OSTEOPOROSIS PROPHYLACTICS | 2009 |
|
RU2412616C1 |
